Results 71 to 80 of about 82,161 (336)
Orphanet Journal of Rare Diseases, 2018 Background Sirolimus has been shown to be effective in patients with lymphangioleiomyomatosis (LAM). We wish to summarize our experience using sirolimus and its effectiveness in LAM patients.
Yongzhong Zhan +9 more
doaj +1 more source
Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial. [PDF]
PLoS ONE, 2012 Sirolimus has been approved for clinical use in non proliferative and proliferative disorders. It inhibits the mammalian target of rapamycin (mTOR) signaling pathway which is also known to regulate ovarian morphology and function.
Matthias Braun +14 more
doaj +1 more source
Cellular antiseizure mechanisms of everolimus in pediatric tuberous sclerosis complex, cortical dysplasia, and non-mTOR-mediated etiologies. [PDF]
, 2018 The present study was designed to examine the potential cellular antiseizure mechanisms of everolimus, a mechanistic target of rapamycin (mTOR) pathway blocker, in pediatric epilepsy cases. Cortical tissue samples obtained from pediatric patients (n
Barry, Joshua +8 more
core +2 more sources
Advanced Healthcare Materials, Volume 14, Issue 7, March 14, 2025.This review highlights emerging bioengineering strategies for treating neointimal hyperplasia in the peripheral vasculature, focusing on approaches that promote re‐endothelialization, modulate smooth muscle cell phenotype, reduce inflammation, mitigate oxidative stress, and optimize biomechanical compliance.
Nikita Wilson John +5 more
wiley +1 more source
Therapeutic Advances in Musculoskeletal Disease, 2020 Objective: To provide real-world data and summarize current clinical evidence on the efficacy and safety of sirolimus in active systemic lupus erythematosus (SLE) patients. Methods: This was a prospective real-world clinical study.
Liying Peng +10 more
semanticscholar +1 more source
Malignant and noninvasive skin tumours in renal transplant recipients. [PDF]
, 2014 Background. Transplant recipients require immunosuppression to prevent graft rejection. This conveys an increased risk of malignancy, particularly skin tumours. There is a need for up-to-date data for the South of England. Method.
Chow, JW +5 more
core +2 more sources
Materials Advances in Devices for Heart Disease Interventions
Advanced Materials, EarlyView.This review examines the crucial role of materials in heart disease interventions, focusing on strategies for monitoring, managing, and repairing heart conditions. It discusses the material requirements for medical devices, highlighting recent innovations and their impact on cardiovascular health.
Gagan K. Jalandhra +11 more
wiley +1 more source
Acute sirolimus overdose: a multicenter case series. [PDF]
PLoS ONE, 2015 There are few data relating to sirolimus overdose in the medical literature. Our objectives were to describe all cases of overdose with sirolimus reported to Swiss, German and Austrian Poisons Centres between 2002-2013.An observational case-series ...
Alessandro Ceschi +7 more
doaj +1 more source
Sirolimus-Induced Rash in a Kidney Transplant Patient
European Journal of Case Reports in Internal Medicine, 2022 Sirolimus is an inhibitor of the mammalian target of rapamycin, which is used in kidney transplant immunosuppression. The clinical spectrum of cutaneous adverse events associated with sirolimus use varies, with maculopapular rash being an uncommon side ...
Zachary Bruss +3 more
doaj +1 more source
Presbycusis: Pathology, Signal Pathways, and Therapeutic Strategy
Advanced Science, EarlyView.In ARHL, the stria vascularis, acting as a cochlear battery, gradually loses its ability to maintain the endocochlear potential, leading to impaired hair cell function and progressive hearing loss. Single‐cell sequencing reveals age‐related cellular changes in the cochlea, providing insights into the underlying mechanisms of aging and potential ...
Xiaoxu Zhao +12 more
wiley +1 more source